Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Goldstein EJ, et al. Among authors: sears p. Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15. Antimicrob Agents Chemother. 2011. PMID: 21844318 Free PMC article. Clinical Trial.
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation.
Mullane KM, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, Holland H, Gregg K, Adachi JA, Pergam SA, Alexander BD, Dubberke ER, Broyde N, Gorbach SL, Sears PS. Mullane KM, et al. Among authors: sears ps. Clin Infect Dis. 2019 Jan 7;68(2):196-203. doi: 10.1093/cid/ciy484. Clin Infect Dis. 2019. PMID: 29893798 Free PMC article. Clinical Trial.
Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.
O'Gorman MA, Michaels MG, Kaplan SL, Otley A, Kociolek LK, Hoffenberg EJ, Kim KS, Nachman S, Pfefferkorn MD, Sentongo T, Sullivan JE, Sears P. O'Gorman MA, et al. Among authors: sears p. J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):210-218. doi: 10.1093/jpids/pix037. J Pediatric Infect Dis Soc. 2018. PMID: 28575523 Clinical Trial.
Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group. Louie TJ, et al. Among authors: sears p. N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812. N Engl J Med. 2011. PMID: 21288078 Free article. Clinical Trial.
Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Babakhani F, et al. Among authors: sears p. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S162-9. doi: 10.1093/cid/cis453. Clin Infect Dis. 2012. PMID: 22752866 Free PMC article.
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group. Cornely OA, et al. Among authors: sears p. Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8. Lancet Infect Dis. 2012. PMID: 22321770 Clinical Trial.
172 results